Brexpiprazole
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Aug 23, 2017 → Apr 22, 2025
NCT ID
NCT03238326About Brexpiprazole
Brexpiprazole is a phase 3 stage product being developed by Lundbeck for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT03238326. Target conditions include Schizophrenia.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05504486 | Approved | Withdrawn |
| NCT04830215 | Approved | Completed |
| NCT04258839 | Phase 3 | Completed |
| NCT03548584 | Phase 3 | Completed |
| NCT03287869 | Phase 3 | Completed |
| NCT03292848 | Phase 1 | Completed |
| NCT03238326 | Phase 3 | Completed |
| NCT01944969 | Phase 3 | Terminated |
| NCT01942785 | Phase 3 | Completed |
| NCT01942733 | Phase 3 | Completed |
| NCT01810783 | Phase 3 | Completed |
Competing Products
20 competing products in Schizophrenia